The Effect of Crisaborole Ointment, 2%, on Pruritus in Patients With Atopic Dermatitis (AD): An Extended Analysis

Gil Yospovitch,1 Eric Simpson,2 Huaming Tan,3 Robert A. Gerber,4 Thomas Lugner,5 Sonja Ständer,7 Wynnis Tom,8 Joseph C. Cappellari,9 Andrew G. Bushmakin,9 William C. Ports,9 Anna M. Tallman9

University of Miami, Miller School of Medicine, Miami, FL, USA; Oregon Health and Science University, Portland, OR, USA; Pfizer Inc., Groton, CT, USA; University Hospital Münster, Münster, Germany; Rady Children’s Hospital-San Diego, San Diego, CA, USA; VICH GmBH, Gießenburg, MD, USA; Pfizer Inc., New York, NY, USA

BACKGROUND
Crisaborole is a novel, low-dose PDE4 inhibitor, a 60% reduction in the mean area under the curve (AUC) was observed for AD-301

METHODS

Conclusions
The results of the extended analysis confirm that crisaborole is effective in treating AD-associated pruritus.


ACKNOWLEDGMENTS

Presented at the 2017 Fall Clinical Dermatology Conference, October 12-15, 2017, Las Vegas, NV.